Here are four things to know about the payment:
- Radioisotopes, specifically Mo-99 and Tc-99m, are crucial for the detection of disease in medical imaging and radiopharmaceuticals. Tc‑99m and its source material, Mo-99, are historically derived from reactors outside the U.S.
- A $10-per-dose add-on payment for radiopharmaceuticals that use Tc-99m derived from domestically produced Mo-99 will begin Jan. 1, 2026.
- CMS said paying providers that use domestically produced Tc-99m radiopharmaceuticals will offset anticipated higher costs.
- “These artificially low, foreign government-subsidized prices have created a disincentive for domestic investments in Mo-99 production infrastructure and a barrier to entry for new producers,” CMS said in a Nov. 1 news release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
